AMERICAN DRUG UTILIZATION REVIEW SOCIETY (EIN 731619985) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2001

Legal Domicile

Principal Officer

SHELLIE KEAST

Phone

4053582472

Tax Period

2024-05-01 to 2025-04-30

AMERICAN DRUG UTILIZATION REVIEW SOCIETY, founded in 2001, is a small nonprofit in the Community Improvement sector that reported $282K in total revenue in fiscal year 2024. Revenue grew 9% year-over-year, indicating healthy expansion.

Mission

AMERICAN DRUG UTILIZATION REVIEW SOCIETY (ADURS) IS A NON-PROFIT ENTITY SUPPORTING INDIVIDUALS ACTIVE IN DRUG UTILIZATION REVIEW. EACH YEAR, A CONFERENCE IS ORGANIZED BY ADURS TO PROVIDE UPDATES FOR STATE MEDICAID PROGRAMS WHERE MEMBERS SHARE INFORMATION, DEVELOP SKILLS AND OBTAIN TRAINING.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $244,700

Investment Income $37,730

Other Revenue $0

TOTAL REVENUE $282,430

Expense Breakdown

Grants Paid $0

Salaries & Benefits $31,046

Fundraising Expenses $0

Other Expenses $268,496

TOTAL EXPENSES $299,542

Year-over-Year Comparison

	2024	2023	Change
Revenue	$282,430	$258,062	+0.1%
Expenses	$299,542	$232,870	+0.3%
Net Income	$-17,112	$25,192	-1.7%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
TERRY COTHRAN	PROGRAM COMM	1.00	Officer Director	$0	$0	$0
AMANDA KIRIAKOPOULOS	DIRECTOR AT	1.00	Officer Director	$0	$0	$0
AIMEE LEWIS	SECRETARY	1.00	Officer Director	$0	$0	$0
PAMELA SMITH	TREASURER	1.00	Officer Director	$0	$0	$0
SHELLIE KEAST	EXECUTIVE DI	5.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$282,430	$299,542	$553,932	$-17,112
2024	$258,062	$232,870	$574,704	$25,192
2023	$237,818	$346,779	$522,688	$-108,961
2022	$250,239	$230,138	$647,744	$20,101
2021	$71,209	$108,672	$693,114	$-37,463
2020	$238,249	$205,264	$626,060	$32,985
2019	$238,192	$225,757	$635,765	$12,435

AMERICAN DRUG UTILIZATION REVIEW SOCIETY